Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intercept Pharmaceuticals (NQ: ICPT )

14.19 -0.85 (-5.65%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intercept Pharmaceuticals

< Previous 1 2 3 4 5 Next >
Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle
Meanwhile, the company is facing a stout rival in the form of Madrigal Pharmaceuticals. 
Via Investor's Business Daily
Where Intercept Pharmaceuticals Stands With Analysts
 
Via Benzinga
Preview: Intercept Pharmaceuticals's Earnings
 
Via Benzinga
Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years
Intercept entered a deal with Amneal, likely lining up a series of new settlements. 
Via Investor's Business Daily
AT&T, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones dropping over 300 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
This Stock That Tripled in 2022 Could Rocket Even Higher in 2023
Potential suitors with heaps of cash to spend are lining up to get a closer look at this company's results. 
Via The Motley Fool
Analyst Ratings for Intercept Pharmaceuticals
 
Via Benzinga
Analyst Ratings for Intercept Pharmaceuticals
Intercept Pharmaceuticals (NASDAQ:ICPT) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Expert Ratings for Intercept Pharmaceuticals
Within the last quarter, Intercept Pharmaceuticals (NASDAQ:ICPT) has observed the following analyst ratings: 
Via Benzinga
Why Applied Molecular Transport Shares Are Trading Lower By Over 55%? Here Are 47 Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
What 6 Analyst Ratings Have To Say About Intercept Pharmaceuticals
Analysts have provided the following ratings for Intercept Pharmaceuticals (NASDAQ:ICPT) within the last quarter: 
Via Benzinga
Why Intercept Pharmaceuticals Stock Is Soaring Today
Investors are cheering the drugmaker's Q3 update. 
Via The Motley Fool
Intercept Pharmaceuticals Crashes After Drug Fails In Cirrhotic Patients
This has been a "historically challenging" population to treat. 
Via Investor's Business Daily
Why Is Intercept Pharmaceuticals (ICPT) Stock Down 20% Today?
Market traders watched Intercept's recent clinical trial with anticipation. Unfortunately, the results fell short and ICPT stock is tanking. 
Via InvestorPlace
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
Via Benzinga
Gartner, Sony, Uber And Other Big Gainers From Tuesday
U.S. stocks closed lower on Tuesday, with the Nasdaq Composite dropping around 100 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Intercept Pharmaceuticals: Q3 Earnings Insights
Intercept Pharmaceuticals (NASDAQ:ICPT) reported its Q3 earnings results on Tuesday, November 1, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Outlook For Intercept Pharmaceuticals
Intercept Pharmaceuticals (NASDAQ:ICPT) is set to give its latest quarterly earnings report on Tuesday, 2022-11-01. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Citigroup To $47? Plus This Analysts Predict $95 For Papa John's
Goldman Sachs cut Citigroup Inc. (NYSE: C) price target from $54 to $47. Citigroup shares fell 0.4% to $41.51 in pre-market trading. 
Via Benzinga
Wells Fargo To Surge Around 20%? Here Are 5 Other Price Target Changes For Monday
Goldman Sachs raised Wells Fargo & Company (NYSE: WFC) price target from $46 to $48. Goldman Sachs analyst Richard Ramsden upgraded the stock from Neutral to Buy. Wells Fargo shares rose 1.1% to $40.68... 
Via Benzinga
Nike, Lululemon, Dick's Sporting Goods And Other Big Losers From Friday
U.S. stocks closed lower with the Dow Jones dropping 500 points on Friday. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday
Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37. 
Via Benzinga
Stocks Struggle For Direction As Choppy Q3 Comes To An End
Markets are having a hard time deciding how to end a dismal week (and month, and quarter). 
Via Talk Markets
FUV Stock Alert: What Is Going on With Arcimoto Today?
Arcimoto (FUV) stock is on a wild ride today after the electric vehicle (EV) company revealed plans for a strategic restructuring. 
Via InvestorPlace
Why Carnival Shares Are Trading Lower By 19%, Here Are 49 Stocks Moving In Friday's Mid-Day Session
Gainers 
Via Benzinga
Wall Street Mixed; Dow Drops Over 50 Points
U.S. stocks traded mixed this morning, with the Dow Jones dropping more than 50 points on Friday. 
Via Benzinga
Intercept Pharmaceutical Stock Sees RS Rating Rise To 91
Intercept Pharmaceutical shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. 
Via Investor's Business Daily
Why Stabilis Solutions Shares Jumped Over 71%; Here Are 70 Biggest Movers From Yesterday
Gainers 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.